Low Dose Intradermal Vaccination Is Superior to High Dose Intramuscular Vaccination for Hepatitis B in Unresponsive Hemodialysis Patients
Open Access
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis Ltd in Renal Failure
- Vol. 29 (3), 285-288
- https://doi.org/10.1080/08860220601166263
Abstract
After two intramuscular (IM) vaccination protocols (40 μg at 0, 1, 2, and 6 months), patients who were unresponsive to hepatitis B vaccination were collected from three HD centers. The aim of this study was to compare the effectiveness of intradermal (ID) and repeated IM vaccination protocols. Thirty-three of 639 HD patients were found to be unresponsive. Patients were randomly assigned into two groups: one to receive 80 μg ID and the other 160 μg IM vaccination protocol. Both ID (p = 0.000) and IM (p = 0.03) groups disclosed statistically significant seroconversion rates six months after the last vaccination dose. The seroconversion rate was 94.1% in the ID and 50% in the IM groups—showing a significant improvement in the ID group (p = 0.011). A low-dose ID is superior to standard IM vaccination protocol and also more cost-effective in unresponsive HD patients.Keywords
This publication has 16 references indexed in Scilit:
- Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patientsJournal of Immune Based Therapies and Vaccines, 2006
- Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patientsKidney International, 2005
- Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedulesVaccine, 2005
- A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysisVaccine, 2005
- Low Dose Intradermal Versus High Dose Intramuscular Hepatitis B Vaccination in Patients on Chronic HemodialysisASAIO Journal, 2005
- The importance of A3 allele in response to hepatitis B vaccine in end-stage renal disease patientsTransplantation Proceedings, 2004
- Peripheral blood dendritic cells and GM-CSF as an adjuvantfor hepatitis B vaccination in hemodialysis patientsKidney International, 2004
- Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patientsVaccine, 2002
- Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigenKidney International, 1998
- Association between an MHC Class II Allele and Clearance of Hepatitis B Virus in the GambiaThe New England Journal of Medicine, 1995